Search
Ipilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigationalIpilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol...
Necitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnIt functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression … Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression
Diacetyl benzoyl lathyrol
go.drugbank.com/drugs/DB11260ApprovedIt is also reported to be a skin conditioning agent.
Mixtures: O HUI white-skin science white calming maskMoricizine
go.drugbank.com/drugs/DB00680ApprovedWithdrawnAn antiarrhythmia agent used primarily for ventricular rhythm disturbances.
Cyproheptadine
go.drugbank.com/drugs/DB00434ApprovedInvestigational[L32474] It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of serotonin syndrome.
Plecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalIt should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
Nilutamide
go.drugbank.com/drugs/DB00665ApprovedInvestigationalTo date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Sebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalSebetralstat is the first and only oral on-demand treatment for HAE, providing a convenient alternative to injectable therapies that have been challenging for patients to use [L53538, A274293].
Betahistine
go.drugbank.com/drugs/DB06698ApprovedInvestigationalIt is thought to reduce symptoms through its actions on histamine receptors. … [A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy.
Products: BETAISTINA MYLAN GENERICS, BETAISTINA DOC GENERICIHydroxyethyl ethylcellulose
go.drugbank.com/drugs/DB14139ApprovedHydroxyethyl ethylcellulose modulates bacterial binding to salivary pellicle; moderately effective in preventing plaque formation.